Mineralys Therapeutics appoints Minji Kim Ph.D. as CBO; splits CFO/CBO roles

Mineralys Therapeutics, Inc.

Adam Levy remains CFO and Secretary; no longer serves as CBO as of Jan 4, 2024.
Dr. Kim brings >20 years biotech BD experience including Jounce Therapeutics and Curis.
Company expects clinical milestones for hypertension drug lorundrostat over next 12–18 months.
Role split supports expanded operations as Mineralys advances late-stage development.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Adam Levy

Chief Business Officer

MLYS · Mineralys Therapeutics, Inc.

Effective: 2024-01-04
Successor: Minji Kim
Filed: January 4, 2024, 6:59 PM ET

As a result, effective January 4, 2024, Adam Levy no longer serves as the Company’s Chief Business Officer.

Appointed

Minji Kim

Chief Business Officer

MLYS · Mineralys Therapeutics, Inc.

Effective: 2024-01-04
Filed: January 4, 2024, 6:59 PM ET

On January 4, 2024, in connection with the appointment of Minji Kim, Ph.D., as Chief Business Officer, the Board of Directors of Mineralys Therapeutics, Inc. (the “Company”) approved splitting the functions of Chief Financial Officer and Chief Business Officer into two roles.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Adam Levy changed role as Chief Business Officer at Mineralys Therapeutics, Inc..

Action: no longer serves as
Role: Chief Business Officer

Exact text from the filing

As a result, effective January 4, 2024, Adam Levy no longer serves as the Company’s Chief Business Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Minji Kim was appointed as Chief Business Officer at Mineralys Therapeutics, Inc..

Action: appointed
Role: Chief Business Officer

Exact text from the filing

On January 4, 2024, in connection with the appointment of Minji Kim, Ph.D., as Chief Business Officer, the Board of Directors of Mineralys Therapeutics, Inc. (the “Company”) approved splitting the functions of Chief Financial Officer and Chief Business Officer into two roles.

View on SEC.gov

Mineralys Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001933414-24-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.